

## **APPLICATION INSTRUCTIONS:**

## **CBCRP BRIDGE FUNDING FOR FELLOWS**

## Contents

Introduction	
Key Dates	2
Overview	3
Evaluation	3
Application Form and Instructions	
Inviting Personnel	2
Section 1: Title Page	∠
Section 2: Applicant/PI	
Section 3: Project Information	5
Section 4: Project Contacts	<u> </u>
Section 5: Budget	<u> </u>
Section 6: Assurances	6
Section 7: Documentation	6
Section 8: Signature Page	10
Appendix A: Cost and Expense Guidelines	12
Appendix B: Other CBCRP Application Policies and Guidelines	14
Contact Information	17

## Introduction

The recent changes to federal research priorities have opened gaps in breast cancer research and training in topic areas that scientists, advocates, clinicians, and policy makers identify as important for understanding, preventing and curing the disease. CBCRP recognizes that these federal re-prioritizations are undermining young investigators at a particularly vulnerable time in their career, therefore we are launching Bridge Funding Awards and re-instituting Full Fellowship Awards for predoctoral and postdoctoral fellows in our 2025-2026 Call for Applications.

We are offering three trainee award opportunities:

- **Bridge Funding for Fellows:** Supports predoctoral and postdoctoral fellows whose federal fellowships have been prematurely terminated and are pursuing breast cancer research in California. \$25,000 direct costs for up to 1 year.
- **Predoctoral Fellowships:** Students enrolled in a doctoral graduate program in California conducting breast cancer research and mentored by an established breast cancer researcher. Up to \$60,000 stipend (plus additional expenses) annually for up to 2 years.
- **Postdoctoral Fellowships:** Breast cancer researchers hired as postdoctoral fellows by a California institution and mentored by an established breast cancer researcher. Up to \$70,000 stipend/salary (plus additional expenses) annually for up to 2 years.

All fellows including those from groups underrepresented in breast cancer research and/or those who wish to pursue careers focused on questions on environmental contributors to breast cancer, health disparities and population-level prevention of breast cancer are encouraged to apply.

In accordance with state and federal law, preference will not be given to trainees based on race, color, ethnicity, gender or national origin.

Applicants may only receive one Bridge Funding grant. Applicants may apply for and be awarded Bridge Funding and a Fellowship in this funding cycle. Review the <a href="Predoctoral and Postdoctoral Fellowship application instructions">Predoctoral and Postdoctoral Fellowship application instructions</a> to learn more about applying for those funding opportunities.

# **Key Dates**

Award	Letter of Intent	<b>Application Deadline</b>	Start Date
Bridge Funding	NA	October 30, 2025	February 1, 2026
Predoctoral Fellowship	January 15, 2026	March 5, 2026	August 1, 2026
Postdoctoral Fellowship	January 15, 2026	March 5, 2026	August 1, 2026

#### **Notes:**

- 1. All submission deadlines are at 12pm noon Pacific Time.
- 2. **Letter of Intent decisions** will be communicated within 5 working days of submission.
- 3. **Other key information**: refer to CBCRP's <u>Call for Applications</u> PDF document.
- **4. Submission of Additional Materials.** No supplemental application materials (e.g., manuscripts or publications) will be accepted after the submission deadline, unless explicitly requested and approved in advance by CBCRP.

## **Overview**

CBCRP is offering \$25,000 awards in bridge funding to mitigate some of the effects that the federal priority changes have had on career plans for early-stage breast cancer researchers. These awards support predoctoral and postdoctoral fellows while they are making the adjustments necessary to address abrupt grant cancellations. Activities could include, but are not limited to, completing analyses, writing and publishing papers, completing studies or conducting searches for new breast cancer-related positions. To be eligible for these awards, fellows must: (1) currently be enrolled at a California institution in a graduate program with a terminal masters or doctoral degree or hold the position of postdoctoral fellow as defined by the institution, (2) work on a project that is focused on breast cancer in any of CBCRP priority areas and (3) show evidence that the project has been terminated prematurely by a federal agency in 2025.

**Purpose/Requirements**: To support the completion of work on a breast cancer project terminated prematurely in 2025 and/or the preparation for transferring the project to a new environment. The project must have been funded by a federal agency and the fellow or mentor must have been officially notified that the grant was terminated between January 6 and October 30, 2025. The fellow may have been previously supported through a training grant or by a mentor's federally funded grant. The mentor must be a breast researcher [i.e., current breast cancer-focused funding or publications since 2023 as either first or senior author with breast cancer in the title or as a major topic]. The Bridge Funding grant application must be submitted by the PI of the terminated award.

**Budget Caps & Project Duration**: up to \$25,000 in direct costs for up to 1 year. Allowable costs include stipend/salary, insurance, tuition, supplies and travel. Indirect costs are not allowed.

## **Evaluation**

The application review will be conducted by the <u>Breast Cancer Research Council</u>. The individuals on the Council performing this review include advocates, clinicians, and scientists from a variety of disciplines. using the following criteria. Scores for each criterion will be weighted equally.

- Response to priorities. How responsive is the research topic to CBCRP priority issues?
- **CBCRP "balance" or underfunded.** The degree to which the research is underrepresented in the CBCRP portfolio and the breast cancer field. To what degree does the research address new gaps in breast cancer research and/or the research pipeline? Will this research address the needs of the underserved, defined as communities or individuals who bear a disproportionally high burden of breast cancer or have disproportionate exposures or conditions linked to breast cancer?
- Impact of Bridge Funding on Applicant. The severity of the unaddressed gap caused by the funding disruption. The degree to which the bridge funding will allow the applicant to continue in a career that furthers breast cancer research. The budget appropriateness and rationale.

# **Application Form and Instructions**

Please review the "SmartSimple Submission Instructions" for the technical instructions for accessing and completing your application. This application instruction document provides guidance for the content of your application.

#### **Inviting Personnel**

The **Invite Personnel** tab in the left sidebar of the grant file enables you to provide access to anyone whom you wish to participate in your application preparation or submission. The personnel roles, their levels of access and the process for sending the invitations are described in the CBCRP SmartSimple instructions.

#### Section 1: Title Page

- **Project Title:** Enter a title that describes the project in lay-friendly language. (Max 100 characters)
- <u>Project Duration</u>: Enter a project duration of 1 year (Project duration must be a whole number).
- **Proposed Project Start Date:** The project start date of February 1, 2026 will autopopulate and is not editable.
- **Proposed Project End Date:** Enter a project end date of January 31, 2027.

### Section 2: Applicant/PI

You must complete all the required information on your Profile page, including the "ORCID ID" field. ORCID provides a persistent digital identifier that distinguishes you from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between you and your professional activities ensuring that your work is recognized. If you have not already obtained an ORCID ID number, you may do

so here: <a href="http://orcid.org/">http://orcid.org/</a> Once you have done so, please enter your 16-digit identifier in the space provided on your profile page in the following format: xxxx-xxxx-xxxx.

#### Section 3: Project Information

Please respond to the following categories and discussion points using the online fields in SmartSimple:

- Lay Abstract (Max 2400 characters): The Lay Abstract should describe:
  - The goals of the original grant and their relationship to breast cancer in lay terms
  - The activities that will be undertaken with the bridge funding
  - The outcomes that the activities will achieve

The abstract should be written using a style and language comprehensible to the general public. Avoid the use of acronyms and technical terms. The scientific level should be comparable to either a local newspaper or magazine article. Avoid the use of technical terms and jargon not a part of general usage.

Applicants must respond to the following categories and discussion points using the online fields provided:

- **CBCRP Research Priorities**. Name the CBCRP priority issue that the research addresses (Community Impact of Breast Cancer; Etiology and Prevention; Biology of the Breast Cell; or Detection, Prognosis and Treatment).
- CSO Research Type(s) and Sub-Type(s). See SmartSimple instructions for more details.
- Subject Area(s). See SmartSimple submission instructions for more details.
- Focus Areas(s). See SmartSimple submission instructions for more details.

#### Section 4: Project Contacts

**Project Personnel. The applicant PI for this application must be the named PI on the federal grant.** Provide contact information and effort for the Applicant Principal Investigator and any Other Significant Contributors on the project. If the Applicant PI is not the fellow, the fellow must be named and included as Key Personnel. Upload biosketches to each of your Key Personnel members in this section, as shown in the SmartSimple instructions. Use the NIH form (version 2020 or later) for each key person and attach it in the Project Personnel section. <u>Limit the length of each biosketch to *no more than* five (5) pages</u>.

#### Section 5: Budget

This section contains several sub-tabs: Institution Contacts, Budget Summary, Budget Details, and Subcontract Budget Details. Complete the information in the Institutional Contacts, Budget Summary, Budget Detail as described in the SmartSimple Application Instructions. Subcontracts are not allowed on this award type.

The maximum duration is 1 year and the direct costs budget cap is \$25,000.

- **Personnel.** The Pi may only receive stipend/salary if they are recognized as a predoctoral or postdoctoral fellow by their institution.
- Student Tuition Fees, Graduate Stipends.
  - **Stipends:** Stipends must adhere to NIH experience scale, or the rates set by their institution with institutional documentation of the alternate payment scale.
  - Tuition: Full tuition and fee costs may be budgeted. Documentation of the institution's tuition and fees structure should be included in the budget justification.
- **Equipment.** Not allowed
- Supplies and expenses. Itemize and justify costs for research supplies and training materials.
- Project meeting travel: Itemize costs for travel to support the research project or trainee career advancement.
- Scientific meeting travel Not allowed
- Indirect (F&A) costs. Not allowed

#### Additional budget guidelines can be found in Appendix A.

#### Section 6: Assurances

Enter assurance information. If available, enter your institutional Federal Wide Assurance (FWA) code or equivalent for Human Subjects, an IACUC Animal Welfare Assurance code for Vertebrate Animals, and equivalent for Biohazard ad DEA Controlled Substance approvals.

#### Section 7: Documentation

Complete and upload all required items. All uploads must be in PDF format. Listed below are the forms and templates you download from SmartSimple, enter text, convert to PDF, and, unless instructed otherwise, re-upload to your application in this section.

Upload Item (Template/Form)	Page limit	Required or optional
Bridge Funding Plan	4	Required (upload to Research Plan field in the Documentation tab)
Biosketches (All Personnel listed on Key Personnel form)	5 (each biosketch)	Required (upload to Project Personnel section)
Human Subjects	No limit	Required
Vertebrate Animals	No limit	Optional
Appendix list and uploads	10	Required

#### **Proposal Template Descriptions:**

#### • Bridge Funding Plan (required)

This section describes the impact, need and plan for the bridge funding and is the primary document that will be used to evaluate the application. <u>Limit the text to 4 pages.</u> References are not included in the page limit.

<u>Format issues:</u> Begin this section of the application using the download template. Subsequent pages of the Research Plan and References should include the principal investigator's name (last, first, middle initial) placed in the upper right corner of each continuation page.

The Bridge Funding Plan and all continuation pages must conform to the following four <u>format</u> <u>requirements</u>:

- 1. The height of the letters must <u>not be smaller than 11 point</u>; Times New Roman or Arial are the suggested fonts.
- 2. Type density, including characters and spaces, must be no more than 15 characters per inch (cpi).
- 3. No more than 6 lines of type within a vertical inch;
- 4. Page margins, in all directions, must be at least ¾ inch.

<u>Suggested content:</u> Proposals for bridge fundings should address the following topics (section page counts are for guidance only):

<u>CBCRP Priority Issue:</u> (about ½ page) Identify the CBCRP Priority Issue (see the <u>CBCRP Call for Applications</u> for their full description) that best matches your project topic and discuss this relationship. If your project addresses more than one CBCRP Priority Issue, then concentrate your discussion on the one priority issue that best matches the project. Address these questions:

- How is your project specific to breast cancer?
- What special aspect of breast cancer is the focus of your research?
- What unique characteristics of breast cancer, especially in the clinical or community settings, make it an ideal target for your research topic?

Research Gap: (up to 1 page) Describe how your research and/or life experience fill gap(s) that have opened in breast cancer research landscape.

<u>Bridge Funding Plans</u>: (up to 2 pages) Describe the short- and long-term career goals of the fellow and how the activities that will be completed with the bridge funding will contribute to achieving the goals. Describe any additional resources that can be leveraged to achieve the goals and how the bridge funding would integrate with those resources.

#### HUMAN SUBJECTS (required)

This form is required to be completed for applications that use Human Subjects, including those in the "Exempt" category. Applications that do not utilize Human Subjects should state "N/A" on the form and upload, as well. Use additional pages, if necessary.

For applications requesting "Exemption" from regular IRB review and approval. Provide sufficient information in response to item #1 below to confirm there has been a determination that the designated exemptions are appropriate. The final approval of exemption from DHHS regulations must be made by an approved Institutional Review Board (IRB). Documentation must be provided before an award is made. Research designated exempt is discussed in the NIH PHS Grant Application #398 <a href="http://grants2.nih.gov/grants/peer/tree\_glossary.pdf">http://grants2.nih.gov/grants/peer/tree\_glossary.pdf</a>. Most research projects funded by CBCRP falls into Exemption category #4. Although a grant application is exempt from these regulations, it must, nevertheless, indicate the parameters of the subject population as requested on the form.

For applications needing full IRB approval: If you have answered "YES" on the Organization Assurances section of the application and designated no exemptions from the regulations, the following seven points must be addressed. In addition, when research involving human subjects will take place at collaborating site(s) or other performance site(s), provide this information before discussing the seven points. Although no specific page limitation applies to this section, be succinct.

- 1. Provide a <u>detailed description of the proposed involvement of human subjects</u> in the project.
- 2. Describe the <u>characteristics</u> of the <u>subject population</u>, including its anticipated number, age range, and health status. It is the policy of the State of California, the University of California, and CBCRP that research involving human subjects must include members of underserved groups in study populations. Applicants must describe how minorities will be included and define the criteria for inclusion or exclusion of any sub-population. If this requirement is not satisfied, the rationale must be clearly explained and justified. Also explain the rationale for the involvement of special classes of subjects, if any, such as fetuses, pregnant women, children, prisoners, other institutionalized individuals, or others who are likely to be vulnerable. Applications without such documentation are ineligible for funding and will not be evaluated.
- 3. Identify the <u>sources of research material</u> obtained from individually identifiable living human subjects in the form of specimens, records, or data. Indicate whether the material or data will be obtained specifically for research purposes or whether use will be made of existing specimens, records or data.
- 4. Describe the <u>plans for recruiting subjects</u> and the consent procedures to be followed, including: the circumstances under which consent will be sought and obtained, who will seek it; the nature of the information to be provided to the prospective subjects; and the method of documenting consent.

- 5. Describe any <u>potential risks</u> —physical, psychological, social, legal, or other. Where appropriate, describe alternative treatments and procedures that might be advantageous to the subjects.
- 6. Describe the <u>procedures for protecting against, or minimizing, any potential risks</u> (including risks to confidentiality), and assess their likely effectiveness. Where appropriate, discuss provisions for ensuring necessary medical or professional intervention in the event of adverse effects on the subjects. Also, where appropriate, describe the provision for <u>monitoring the data collected</u> to ensure the safety of subjects.
- Discuss why the risks are reasonable in relation to the anticipated benefits to subjects, and in relation to the importance of knowledge that may be reasonably expected to result

#### **Documentation of Assurances for Human Subjects**

In the Assurances tab, if available at the time of submission, include official documentation of the approval by the IRB, showing the title of this application, the principal investigator's name, and the approval date. Do not include supporting protocols. Approvals that are obtained under a different title, investigator or organization are *not* acceptable, unless they cross reference- the proposed project. Even if there is no applicant institution (i.e., an individual PI is the responsible applicant) and there is no institutional performance site, an USPHS approved IRB must provide the assurance. If review is pending, final assurance should be forwarded- to CBCRP as soon as possible, but **no later than February 1, 2026**. Funds will not be released until all assurances are received by CBCRP. If the research organization(s) where the work with human subjects will take place is different than the applicant organization, then approvals from the boards of each will be required.

#### **Data and Safety Monitoring Boards (DSMB)**

Applications that include Phase I-III clinical trials may be required to provide a data and safety monitoring board (DSMB) as described in the NICI policy release, <a href="http://grants.nih.gov/grants/guide/notice-files/not98-084.html">http://grants.nih.gov/grants/guide/notice-files/not98-084.html</a>. This ensures patient safety, confidentiality, and guidelines for continuing or canceling a clinical trial based on data collected in the course of the studies. CBCRP may require documentation that a DSMB is in place or planned prior to the onset of the trial.

#### • VERTEBRATE ANIMALS (optional)

This form is required only for applications that use Vertebrate Animals. <u>Limit the text to two</u> pages.

If you have answered "YES" to the Vertebrate Animals item on the Organizations Assurances page of your application, then following five points must be addressed. When research involving vertebrate animals will take place at collaborating site(s) or other performance site(s), provide this information before discussing the five points.

- 1. Provide a detailed description of the <u>proposed use</u> of the animals in the work outlined in the Research Plan. Identify the species, strains, ages, sex, and numbers of animals to be used in the proposed work.
- 2. <u>Justify the use of animals</u>, the choice of species, and the numbers used. If animals are in short supply, costly, or to be used in large numbers, provide an additional rationale for their selection and numbers.
- **3.** Provide information on the veterinary care of the animals involved.
- 4. Describe the <u>procedures for ensuring that discomfort, distress, pain, and injury will be limited</u> to that which is unavoidable in the conduct of scientifically sound research. Describe the use of analgesic, anesthetic and tranquilizing drugs, and/or comfortable restraining devices, where appropriate, to minimize discomfort, distress, pain, and injury.
- **5.** Describe any <u>methods of euthanasia</u> to be used and the reasons for its selection. State whether this method is consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. If it is not, present a justification for not following the recommendations.

#### **Documentation of Assurances for Vertebrate Animals**

Grants will not be awarded for research involving vertebrate animals unless the program for animal care and welfare meets the standards of the AAALAC or the institution has a U.S. Public Health Service assurance. In the appendix, if available at the time of submission, include official documentation of institutional review committee approval showing the title of this application, the principal investigator's name, and the inclusive approval dates. Do not include supporting protocols. Approvals obtained under a different title, investigator or institutions are not acceptable unless they cross-reference the proposed project. If review is pending, final assurances should be forwarded to CBCRP as soon as possible, but **no later than February 1, 2026**. Funds will not be released until all assurances are received by CBCRP.

#### • APPENDIX LIST (Required)

Attach the following items to the appendix.

- The abstract and specific aims of the original grant
- The grant termination letter

The appendix may <u>not</u> be more than 10 pages in length.

#### Section 8: Signature Page

Once all online and downloaded templates have been completed and uploaded to SmartSimple, the application is ready to be submitted to your institution's signing official. You must click "Submit to Signing Official" to complete this step. Your institution's signing official will receive an email notification to log in, review, and either submit the application, or send the application back to the Applicant PI for revision. Note: The signing official must complete this step prior to

the application deadline. Please plan submission timelines accordingly. See SmartSimple instructions for further details.

• **Electronic submission:** the deadline for electronic submission of the <u>complete</u> <u>application</u> by your Institutional Signing Official is **October 30, 2025** (12 noon Pacific Standard Time)

# **Appendix A: Cost and Expense Guidelines**

#### 1) Personnel

- The Budget Summary line item for Personnel should reflect the total cost of all
  individuals identified as supported by the grant and their level of effort. In the personnel
  section of the application, be sure to name all individuals to be supported by the grant
  and provide their percent effort (months devoted to the project). All paid individuals
  must also be listed on the budget.
- Follow the NIH Guidelines and Calculation scheme for determining Months Devoted to Project, available at the links below:
  - NIH Guidelines:
  - http://grants.nih.gov/grants/policy/person months faqs.htm
  - NIH Calculation Scheme:
     http://grants.nih.gov/grants/policy/person months conversion chart.xls
- Provide a justification for all budgeted personnel, identifying each individual by name, role on the project, and proposed effort. When computing salary for key personnel, use only the base salary at the applicant organization, excluding any supplementary income (e.g., clinical or consulting incomes). The program does not enforce a salary cap, as long as the overall budget adheres to the costs & expenses guidelines and the amount requested stays within the allowable costs.

#### 2) Student Tuition Fees, Graduate Student Stipends

Stipend may be budgeted as salary if the institution pays these expenses through a
personnel line item. Tuition remission will be considered compensation and should not
offset other financial aid. Please provide documentation of current institution rates
and/or scales for requested tuition & fees and stipends.

#### 3) Other Project Expenses (no IDC)

- Include expected costs for supplies and other research expenses not itemized elsewhere. Costs should be added to the "Not-Included in IDC" sub-categories only. Cost should be broken out by year, include overall cost by category, an itemized sub-category list, and description of costs. Examples of justifications meet these requirements are as follows:
  - General lab supplies, chemicals, and biochemicals and chemicals (Year 1: \$16,123) – This cost includes purchasing routine lab supplies such as plasticware and glassware for various preparations and disposable items, including pipettes, filter units, conical tubes, gloves, etc. Research cigarettes will be needed for the studies. The use of biochemicals, proteins, extracellular matrix substances, and molecular biology enzymes, markers for various protein and nucleic acid studies will be needed throughout the study. Materials to run various agarose and polyacrylamide gels are required. CO2, dry ice, liquid nitrogen, oxygen, and various small instruments are necessary for the daily procedures performed in a

- molecular biology laboratory. Chemicals used throughout the various studies will be required to produce various solutions.
- Cell isolation and culture (Year 1: \$3000/year) The project will employ the culture of cardiac myocytes from the various mouse models. This cost will cover collagenase, LiberaseTM, trypsin, serum, antibiotics, media, and other various chemicals and supplies related to these studies.
- Office Supplies / Computer (Year 1: \$5,000/year) Costs are required to purchase office supplies and computer software for statistical analysis.
- Pooled expenses (e.g. insurance surcharges such as GAEL, system wide networking surcharges, and other pooled training and facilities expenses) may be allowed as a direct cost at the discretion of the Program with certification of the following: 1) the project will be directly supported by the pooled expenses, 2) the pooled expenses have been specifically excluded from the indirect cost rate negotiation, and 3) the pooled expenses have been allocated consistently over time within the organization. Please explain any requested pooled expense requests in the budget justification.
- Advocate Expenses. Include any travel, meeting, and consultation costs/fees associated with advocate engagement.

#### 4) Equipment (Unit Cost over \$5,000)

Not Allowed

#### 5) Travel

Please provide itemized details as to the number of travelers and mode of travel for each travel category relevant to your project.

- <u>Travel CBCRP Meeting</u>: Not required.
- <u>Travel Project Related</u>: Project-related travel expenses are allowable only for travel directly related to the execution of the proposed research activities. Label such expenses as "Travel Project Related." These expenses must be fully justified in the budget justification.
- Travel Scientific Meetings: Not allowed.

#### 6) Service Contracts and Consultants

Not Allowed.

#### 7) Subcontracts

Not Allowed.

#### 8) INDIRECT (F&A) COSTS

Not Allowed

# Appendix B: Other CBCRP Application Policies and Guidelines

#### **Eligibility and Award Limits**

- 1. Any individual or organization in California may submit an application. The research must be conducted primarily in California. We welcome investigators from community organizations, public or privately-owned corporations and other businesses, volunteer health organizations, health maintenance organizations, hospitals, laboratories, research institutions, colleges, and universities. Applicants at California-based Nonprofit Institutions: CBCRP will accept applicants from PIs at non-profit organizations or institutions, provided that the organization can manage the grant and demonstrate financial health. The organization must also meet our liability insurance requirements. If the application is recommended for funding, the University will collect additional information, such as tax ID numbers and financial reports, to review the organization during the pre-funding process to ensure all financial management and project management eligibility criteria can be met.
- **2.** We encourage researchers new to breast cancer to apply. Applicants who have limited experience in breast cancer research should collaborate with established breast cancer researchers.
- **3.** Pls who have previously been funded by CBCRP are welcome to apply, but the <u>research aims</u> must be distinct from their previous CBCRP grants.
- **4. Multiple applications and grant limits for PIs.** A PI may submit more than one application, but each must have unique specific aims. <u>Applicants are limited to a maximum of two (2) grants either as PI or co-PI</u>, and these must be in different award types. The Program and Policy Initiative grants are not included in this limit. A PI may have more than one Program or Policy Initiative grant in a year.
- **5. University of California Campus Employees:** In accord with University of California policy, investigators who are University employees and who receive any part of their salary through the University must submit grant proposals through their campus contracts and grants office ("Policy on the Requirement to Submit Proposals and to Receive Awards for Grants and Contracts through the University," Office of the President, December 15, 1994). Exceptions must be approved by the UC campus where the investigator is employed.

#### Policy on Applications from PIs with Delinquent CBCRP Grant Reports

Pls with current CBCRP grant support will <u>not</u> be eligible to apply for additional funding unless the required scientific and fiscal reports on their existing grants are up-to-date. This means that **Progress/Final Scientific Reports or Fiscal Reports that are more than one month overdue may** 

**subject a Cycle 32 application to disqualification** unless the issue is either, (i) addressed by the PI and Institution within one month of notification, or (ii) the PI and Institution have received written permission from CBCRP to allow an extension of any report deadlines.

#### **Confidentiality**

CBCRP maintains confidentiality for all submitted applications with respect to the identity of applicants and applicant organizations, all contents of every application, and the outcome of reviews. For those applications that are funded CBCRP makes public, (i) the title, principal investigator(s), the name of the organization, and award amount in a "Compendium of Awards" for each funding cycle, (ii) the costs (both direct and indirect) in CBCRP's annual report, (iii) the project abstract and progress report abstracts on the CBCRP website. If the Program receives a request for additional information on a funded grant, the principal investigator and institution will be notified prior to the Program's response to the request. Any sensitive or proprietary intellectual property in a grant will be edited and approved by the PI(s) and institution prior to release of the requested information.

No information will be released without prior approval from the PI for any application that is not funded.

#### **Human Subjects and Vertebrate Animal Use**

Approvals for use of human material and animal research subjects are not required at the time of application. Applicants are encouraged to apply to the appropriate board or committee as soon as possible in order to expedite the start of the project, and you must do so before or within 21 days of notification that an award has been offered. This deadline may be negotiable depending on the circumstances of the proposal. If all reasonable efforts are not made to obtain appropriate approvals in a timely fashion, funds may be reallocated to other potential grantees' proposed research projects.

#### **Award Decisions**

Applicants will be notified of their funding status by December 31, 2025. The written application critique from the review committee, the merit score average, component scores, percentile ranking, and programmatic evaluation are provided at a later time. Some applications could be placed on a 'waiting list' for possible later funding.

#### **Appeals of Funding Decisions**

RGPO strives to resolve issues raised throughout the grantmaking lifecycle from funding decisions to project closeout. Before submitting an appeal or grievance, applicants are encouraged to discuss their concerns with the appropriate program officer or program director.

The only basis on which an appeal regarding the funding decision of a grant application will be considered is in the case of an alleged error in, or violation of the peer review procedures

and/or process. Appeals based on substantive disagreement with the peer review evaluation will not be considered. In such cases, applicants may resubmit applications in a subsequent grant cycle.

Applicant appeals must be made to the program within 30 days of the funding notification. If discussions with the program do not satisfactorily resolve an applicant's issue, either the applicant or the program may contact the RGPO Executive Director for resolution. If resolution is not achieved, or if the applicant believes that a violation has occurred that has not been adequately addressed through these efforts, a formal appeal may be filed with the Vice President of Research and Innovation.

#### **Pre-funding Requirements**

Following notification by CBCRP of an offer of funding, the PI and applicant organization must accept and satisfy normal funding requirements in a timely manner. Common pre-funding items include:

- 1. Supply approved indirect (F&A) rate agreements as of the grant's start date and any derived budget calculations.
- 2. Supply any missing application forms or materials, including detailed budgets and justifications for any subcontract(s).
- 3. IRB applications or approvals pertaining to the award.
- 4. Resolution of any scientific overlap issues with other grants or pending applications.
- 5. Resolution of any Review Committee and Program recommendations, including specific aims, award budget, or duration.
- 6. Modify the title and lay abstract, if requested.

Note: If the federally terminated grant is reinstated while the Bridge Funding award is active, the PI and applicant organization must notify CBCRP within 30 days.

#### <u>Publications Acknowledgement</u>

All scientific publications and other products from a RGPO-funded research project must acknowledge the funding support from UC Office of the President, with reference to the specific CBCRP funding program and the assigned grant ID number.

#### **Open Access Policy**

As a recipient of a California Breast Cancer Research Program (CBCRP) grant award, you will be required to make all resulting research findings publicly available in accordance with the terms of the Open Access Policy of the Research Grants Program Office (RGPO) of the University of California, Office of the President (UCOP). This policy, which went into effect on April 22, 2014, is available here: <a href="https://www.ucop.edu/research-grants-program/grant-administration/rgpo-open-access-policy.html">https://www.ucop.edu/research-grants-program/grant-administration/rgpo-open-access-policy.html</a>

#### **Grant Management Procedures and Policies**

All CBCRP grant recipients must abide by other pre- and post-award requirements pertaining to Cost Share, Indirect Cost Rates, Monitoring & Payment of Subcontracts, Conflict of Interest, Disclosure of Violations, Return of Interest, Equipment and Residual Supplies, Records Retention, Open Access, and Reporting. Details concerning the requirements for grant recipients are available in a separate publication, the University of California, Office of the President, "RGPO Grant Administration Manual." The latest version of the Manual and programmatic updates can be obtained from the Program's office or viewed on our website:

https://www.ucop.edu/research-grants-program/grant-administration/index.html

## **Contact Information**

- Technical support and questions about application instructions and forms should be addressed to the Research Grant Programs Office Contracts and Grants Unit: RGPOGrants@ucop.edu
- For scientific or research inquiries, please contact Katherine McKenzie, PhD Senior Program Officer, CBCRP: <u>Katherine.McKenzie@ucop.edu</u>

The California Breast Cancer Research Program is part of the Research Grants Program Office of the University of California, Office of the President.